Since its 1996 listing on the London and Zagreb Stock Exchanges, PLIVA has made notable advancements in internationalizing its business and implementing global and innovative strategies. PLIVA is a rather unique company with investments in both research and development. With over 400 patents in its possession, PLIVA has proven the high calibre of its R&D capabilities, most notably through the discovery of its blockbuster - azithromycin. This macrolide antibiotic, globally known as Zithromax (under license to Pfizer) or Sumamed, is the top selling antibiotic in its class. PLIVA is the largest pharmaceutical company by turnover in Central and Eastern Europe and continues to expand its operations with recent acquisitions of pharmaceutical and R&D companies in the Czech Republic, France, Germany, United Kingdom and USA. With increasing efforts concentrating on the global pharmaceuticals market, PLIVA has divested its cosmetics, food and agrochemicals production units as stand alone companies. PLIVA consists of 44 legal entities, has 5 major business divisions (research, fine chemicals, pharmaceutical, OTC, DDI) and 9 strategic/corporate divisions (development, regulatory affairs, finance, human resources, IT, quality assurance, legal affairs, corporate communications and engineering). PLIVA employs almost 7500 people in 33 countries (including 120 IT professionals not including out-of-house consultants), has 5 main production locations (Croatia, Czech Republic, Poland, Germany and USA) and 43 subsidiaries in 23 countries.
|
